3 Reasons GlaxoSmithKline plc Stock Could Rise

GlaxoSmithKline's transition period has been far rougher than expected, causing shares to drop nearly 15% last quarter. Even so, there are three compelling reasons to believe that shares could rally heading into the end of the year.

Aug 20, 2014 at 12:13PM

Like most big pharmas these days, the U.K.'s GlaxoSmithKline (NYSE:GSK) is going through a transitory period as key medicines like Advair and Lovaza lose market share to new products. Compounding these problems, Glaxo is facing bribery allegations that have now spread to several countries in key emerging markets. 

Mk Bh

Source: Wall Street Journal 

And as a result of the consistent bad news, Glaxo's stock has thus slumped nearly 15% in the past quarter.

GSK Chart

GSK data by YCharts

Despite these major headwinds facing the company, I believe there are three compelling reasons why Glaxo's stock could rebound. But before getting into the reasons, it's important to remember that there are no guarantees that a stock will rise or fall -- any number of outside factors (market crash, other unforeseen bad news for GlaxoSmithKline, etc.) could intervene. With that in mind, let's get started.

Reason No. 1
The recent price drop could generate interest in a buyout or merger with a U.S.-based pharma seeking a coveted tax inversion. Pfizer reportedly offered up to $118 billion for AstraZeneca earlier this year, mainly for the tax benefits. And given that Glaxo's market cap has recently fallen to a hair under $114 billion, it could now be a viable alternative for Pfizer, especially if its pursuit of AstraZeneca ultimately fails.

Although Glaxo's CEO Sir Andrew Witty has downplayed any possible megamergers in the near term, there are intriguing synergies between Glaxo and Pfizer's product portfolios that could make such a deal worth pursuing by both companies. 

Reason No. 2
Glaxo's respiratory medicines have been at the core of its commercial problems, but there is hope moving forward. Although the company was expecting sales of newer products like Anoro, Breo, and Incruse would offset declining Advair sales, 
this strategy hasn't panned out largely because opinion leaders like Express Scripts Holding Company have excluded Breo from their list of medicines eligible for reimbursement

Medicare Part D coverage for Anoro and Breo has nonetheless started to increase in recent quarters, slowly building market access for these new drugs. Moreover, Glaxo is expected to gain additional regulatory approvals for these medicines, as well as other experimental products, in the near future.

Glaxo is thus projected to return to growth by 2015, giving the company an attractive forward price-to-earnings ratio of roughly 13 at current levels. Put simply, Glaxo shares look cheap following this double-digit drop in price. 

Reason No. 3
Perhaps one of the best reasons why investors might find Glaxo shares compelling at current levels is its handsome dividend yield of over 5%. Even though management decided to cut back on share repurchases for the time being, they are continuing the trend of increasing annual dividend payments at a nice clip. Compared to the second quarter a year ago, for example, Glaxo's dividend has increased by a noteworthy 6%. As such, Glaxo presently sports one of the 
highest yields among healthcare stocks.

Foolish wrap-up
The convergence of bad news emanating from Glaxo lately has certainly taken its toll of share price. Even so, this dip has created an attractive entry point for investors with a long-term outlook, in my opinion.

While the buyout/merger hypothesis may turn out to be little more than informed speculation so to speak, Glaxo is on track to generate top-line growth next year and its track record of increasing dividend payments will undoubtedly garner attention from income investors. So while this transitory period has been a rough time for the company and its investors alike, I think there are fundamentally sound reasons to be optimistic going forward.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information